Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention BioMarin Pharmaceutical, the most common co-covered peer. Source depth averages 4 original sources per story, versus 6 across the same-window beat baseline.
Last mentioned: Feb 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention BioMarin Pharmaceutical, the most common co-covered peer. Source depth averages 4 original sources per story, versus 6 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.8. We currently track 1 Healthcare story that mention Myriad Genetics, all published on February 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Myriad Genetics. Shared-story counts are live from our verified record — not editorial picks.
A critical wave of fourth-quarter 2025 earnings previews highlights a sector-wide focus on clinical execution and commercial scaling for mid-to-large cap biotech players. Summit Therapeutics' ivonescimab progress and BioMarin's Voxzogo expansion remain the primary catalysts for investor sentiment as the industry navigates a disciplined capital environment.
Source: Seeking Alpha · Seeking Alpha
Myriad Genetics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
